FDA strikes a blow for Glaxo

Glaxo Wellcome, the British pharmaceuticals giant, was boosted yesterday by a landmark decision by the US Food and Drug Administration to extend drug patents to bring them into line with international standards.

The decision, which is the latest episode in the company's fight against manfacturers of generic rivals, lifts months of uncertainty hanging over Glaxo's top-selling drug, Zantac.

The FDA decision was made to comply with a law signed by President Bill Clinton following last year's Gatt agreement on world trade. But the move drew protests from consumer groups and makers of generic drugs, anxious to challenge branded drugs as their patents expire.

From 8 June the FDA will award patents for 20 years from the time of application, rather than the existing period of 17 years from the time of approval.

Companies with existing patents will be allowed to choose the longer of the two periods. For Glaxo's blockbuster ulcer drug, Zantac, the ruling will mean its patent expires in July 1997 instead of December this year. This will have a big impact on the drug maker's earnings, as Zantac makes up more than 40 per cent of its total world sales. The US is by far the biggest market for the drug.

The decision means a setback for companies such as Geneva and Novopharm, which are poised to enter the market with generic versions of Zantac.

According to Merrill Lynch, sales of branded Zantac could fall by as much as 40 per cent in the US following the patent expiry in July 1997. Merrill Lynch estimates sales of the drug could reach $1.36bn for the 12 months to 30 June but forecasts sales of only $696m for the year from July 1997, coinciding with the first 12-month period after the patent expiry.

Its prediction for the following year is $278m as the generic alternatives establish themselves in the marketplace.

These figures suggest that the 19-month extension granted by the FDA will be worth well over pounds 1bn of extra sales to Glaxo. Its shares rose 2.5p to 729p.

Some US congressmen have expressed anger at the FDA decision, saying it will mean higher costs for the taxpayer as patients on federal programmes such as Medicare and Medicaid continue to pay higher prices for Zantac and about a hundred other branded drugs that stand to benefit from patent extensions.

Senator David Pryor of Arkansas, the ranking Democrat on the Senate's special committee on ageing, suggested legislation might be introduced to correct what he sees as a windfall to the big drug companies. Other congressmen consider the FDA has little choice but to comply with Gatt standards.

Start your day with The Independent, sign up for daily news emails
News
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Digital Optimisation Executive - Marketing

£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...

Recruitment Genius: Financial Reporting Manager

£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Day In a Page

Sepp Blatter resignation: The beginning of Fifa's long road to reform?

Does Blatter's departure mean Fifa will automatically clean up its act?

Don't bet on it, says Tom Peck
Charles Kennedy: The baby of the House who grew into a Lib Dem giant

The baby of the House who grew into a Lib Dem giant

Charles Kennedy was consistently a man of the centre-left, dedicated to social justice, but was also a champion of liberty and an opponent of the nanny-state, says Baroness Williams
Syria civil war: The harrowing testament of a five-year-old victim of this endless conflict

The harrowing testament of a five-year-old victim of Syria's endless civil war

Sahar Qanbar lost her mother and brother as civilians and government soldiers fought side by side after being surrounded by brutal Islamist fighters. Robert Fisk visited her
The future of songwriting: How streaming is changing everything we know about making music

The future of songwriting

How streaming is changing everything we know about making music
William Shemin and Henry Johnson: Jewish and black soldiers receive World War I Medal of Honor amid claims of discrimination

Recognition at long last

Jewish and black soldiers who fought in WWI finally receive medals after claims of discrimination
Beating obesity: The new pacemaker which helps over-eaters

Beating obesity

The new pacemaker which helps over-eaters
9 best women's festival waterproofs

Ready for rain: 9 best women's festival waterproofs

These are the macs to keep your denim dry and your hair frizz-free(ish)
Cycling World Hour Record: Nervous Sir Bradley Wiggins ready for pain as he prepares to go distance

Wiggins worried

Nervous Sir Bradley ready for pain as he prepares to attempt cycling's World Hour Record
Liverpool close in on Milner signing

Liverpool close in on Milner signing

Reds baulk at Christian Benteke £32.5m release clause
On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

On your feet!

Spending half the day standing 'reduces risk of heart attacks and cancer'
With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

The big NHS question

Why are there so few new GPs when so many want to study medicine?
Big knickers are back: Thongs ain't what they used to be

Thongs ain't what they used to be

Big knickers are back
Thurston Moore interview

Thurston Moore interview

On living in London, Sonic Youth and musical memoirs
In full bloom

In full bloom

Floral print womenswear
From leading man to Elephant Man, Bradley Cooper is terrific

From leading man to Elephant Man

Bradley Cooper is terrific